Hematopoietic stem cell mobilizer

What are Hematopoietic stem cell mobilizer?

Hematopoietic stem cell mobilizer binds to the CXCR4 chemokine receptor and inhibits the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha). This leads to mobilization of hematopoietic stem cells to the peripheral blood. The hematopoietic stem cells (CD34+ cells) are collected from the peripheral blood and used for autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma. Hematopoietic stem cells produce all types of blood cells so autologous transplantation restores normal production of the blood cells.

(stem sel MOH-bih-lih-ZAY-shun) A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.

Plerixafor (Mozobil, AMD3100) is a bicyclam molecule which reversibly inhibits SDF-1 binding to CXCR4, promoting HSC mobilization. Plerixafor is approved to be used in combination with G-CSF for stem cell mobilization in patients with myeloma and lymphoma.

Hematopoietic stem cell transplant (HPSCT), sometimes referred to as bone marrow transplant, involves administering healthy hematopoietic stem cells to patients with dysfunctional or depleted bone marrow. There are several types of HPSCT in clinical use, and transplanted cells may be obtained from several sources.